Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
What strategies do you implement to control the nausea from Enhertu?
Related Questions
What is your recommended treatment sequencing strategy in patients with HER2+ breast cancer and leptomeningeal carcinomatosis?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
How will you sequence Dato-DXd among available therapies for HR positive, HER2-negative metastatic breast cancer?
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
How do you reconcile data from PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic HER 2+ breast cancer?
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic ER+ HER2+ breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2024?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
How will you weigh the positive PFS but negative OS benefit when discussing Dato-DXd with patients?
For patients with HbA1c >6 can the INAVO regimen still be utilized if the patient is otherwise fit and has a strategy for ongoing glycemic control?
